Baidu
map

Nature:阿尔茨海默氏症有望接种疫苗预防

2013-04-01 蓝建中 新华网

日本研究人员一项最新研究成果显示,向患有阿尔茨海默氏症的实验鼠血管中注射一种基因物质,成功使得负责分解β淀粉样蛋白的基因在脑内发挥作用,实验鼠的病症得到明显改善。这使得将来有可能以接种疫苗的形式来预防这种常见疾病。 一种名为脑啡肽酶的分解酶发挥着防止β淀粉样蛋白蓄积的功能,β淀粉样蛋白的蓄积被认为是导致阿尔茨海默氏症的原因。但随着年龄增长,一些人负责生成脑啡肽酶的基因功能出现衰退,从而导致发病。

日本研究人员一项最新研究成果显示,向患有阿尔茨海默氏症的实验鼠血管中注射一种基因物质,成功使得负责分解β淀粉样蛋白的基因在脑内发挥作用,实验鼠的病症得到明显改善。这使得将来有可能以接种疫苗的形式来预防这种常见疾病。

一种名为脑啡肽酶的分解酶发挥着防止β淀粉样蛋白蓄积的功能,β淀粉样蛋白的蓄积被认为是导致阿尔茨海默氏症的原因。但随着年龄增长,一些人负责生成脑啡肽酶的基因功能出现衰退,从而导致发病。

日本理化学研究所18日发表公报称,该所研究人员和长崎大学研究人员合作,将脑啡肽酶的基因植入一种无病原性病毒,并将其注射到患病实验鼠血管中。结果显示,这种基因只在实验鼠脑内产生作用,帮助形成脑啡肽酶,在其他器官中并无功用。研究发现,接受注射的实验鼠脑内β淀粉样蛋白比其他患病实验鼠减少约30%,学习和记忆能力也恢复到与正常实验鼠相当的水平。

这种基因注射疗法较一些脑神经疾病的基因疗法更简单易行,甚至将来有可能实现阿尔茨海默氏症的“预防接种”。相关论文已经刊登在英国《科学报告》(Scientific Reports)杂志上。

doi:10.1038/srep01472
PMC:
PMID:

Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice

Nobuhisa Iwata; Misaki Sekiguchi; Yoshino Hattori; Akane Takahashi; Masashi Asai; Bin Ji; Makoto Higuchi; Matthias Staufenbiel; Shin-ichi Muramatsu; Takaomi C. Saido

Accumulation of amyloid-β peptide (Aβ) in the brain is closely associated with cognitive decline in Alzheimer's disease (AD). Stereotaxic infusion of neprilysin-encoding viral vectors into the hippocampus has been shown to decrease Aβ in AD-model mice, but more efficient and global delivery is necessary to treat the broadly distributed burden in AD. Here we developed an adeno-associated virus (AAV) vector capable of providing neuronal gene expression throughout the brains after peripheral administration. A single intracardiac administration of the vector carrying neprilysin gene in AD-model mice elevated neprilysin activity broadly in the brain, and reduced Aβ oligomers, with concurrent alleviation of abnormal learning and memory function and improvement of amyloid burden. The exogenous neprilysin was localized mainly in endosomes, thereby effectively excluding Aβ oligomers from the brain. AAV vector-mediated gene transfer may provide a therapeutic strategy for neurodegenerative diseases, where global transduction of a therapeutic gene into the brain is necessary.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
    2013-05-30 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1879457, encodeId=e29418e94571c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 30 06:23:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632325, encodeId=e721163232570, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Sun Aug 25 13:23:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816567, encodeId=7c96181656e22, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Nov 12 22:23:00 CST 2013, time=2013-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1953631, encodeId=d95719536318f, content=<a href='/topic/show?id=ebace05389b' target=_blank style='color:#2F92EE;'>#疫苗预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70538, encryptionId=ebace05389b, topicName=疫苗预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Jun 05 13:23:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990353, encodeId=9d9a1990353d2, content=<a href='/topic/show?id=b8eb9e78216' target=_blank style='color:#2F92EE;'>#阿尔茨海默氏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97782, encryptionId=b8eb9e78216, topicName=阿尔茨海默氏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b952312, createdName=zhs3882, createdTime=Tue Nov 19 08:23:00 CST 2013, time=2013-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817590, encodeId=78aa181e59074, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Wed May 15 15:23:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469944, encodeId=8ad51469944d1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Apr 03 09:23:00 CST 2013, time=2013-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5576, encodeId=1eb655e6f3, content=早期也许有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 02 08:05:00 CST 2013, time=2013-04-02, status=1, ipAttribution=)]
    2013-04-02 匿名用户

    早期也许有用

    0

相关资讯

J Am Geriatr Soc:口腔健康或会影响患痴呆症概率

    记得每天刷牙能够保持你的记忆力在未来几年里依然敏捷。一项新研究指出,口腔健康习惯可能会影响患痴呆症的概率。另外,口腔疾病引发的炎症通常与心脏病和糖尿病等疾病有关联。 年至2010年间,研究人员跟踪调查了美国加利福尼亚州近5500名退休居民,结果发现,那些刷牙次数少于每天一次的参与者比那些每天刷三次牙的人患痴呆症的几率可能高了近56%,并且这在女性中更为明显

卫材公布E2609 阿尔茨海默氏症I期临床数据

卫材(Eisai)今天在加拿大温哥华举行的2012年阿尔茨海默氏症协会国际会议(AAIC)上发布了E2609的首批临床数据,这是一种BACE(β淀粉样前体蛋白裂解酶)抑制剂。 这种新颖的化合物,由卫材在英国、日本及美国的各中心合作发现。 在英国,卫材拥有一个世界最大的老年痴呆症私人研究小组。通过与英国的合作伙伴及日本的同事们协作努力,该小组已成为关键性神经系统新发现的一部分,包括潜在的癫痫新药

Mol Psychiatry:阿尔茨海默氏症药物Dimebon或仍具有治疗潜力

近日,西奈半岛学院医学院研究人员领导的国际小组已经发现,一种已先前在阿尔茨海默氏病的临床试验中取得相互矛盾的结果药物能有效地停止阿尔茨海默氏症疾病小鼠模型的疾病早期阶段的记忆恶化和大脑病理进展。研究结果于7月31日发表在在Molecular Psychiatry杂志上,该研究证实了这种化合物仍具有治疗潜力,并可能促使开展处于疾病早期阶段患者的相关临床试验。 Latrepirdine又称为Di

Neuron:线粒体长度异常会促进神经变性疾病发展

哈佛医学院研究人员发现,产生能量的细胞器即线粒体的长度异常会促进神经变性疾病如阿尔茨海默氏症的发生于发展。 近来,越来越多的研究关注于阿尔茨海默氏症和tau蛋白有关的疾病中的线粒体作用,但线美国马萨诸塞州总医院的博士后研究员Brian DuBoff研究表示:粒体与上述疾病之间的因果关系仍是未知的。更深入地了解线粒体的功能和阿尔茨海默氏症之间的关系可能会引导我们在未来开发更有针对性的治疗手段。相关

Neurotez公司血清瘦素(Leptin)获美国专利

Neurotez公司宣布,血清瘦素(Leptin)获美国专利,专利涵盖Leptin用于阿尔茨海默氏症(AD)的治疗及通过调节大脑中淀粉样多肽的积累来改善认知功能的恢复。 专利签发的同时,Neurotez公司也完成了重组Leptin的GMP生产及用于研究性新药申请(IND)支持性研究的准备。 临床前体内外实验数据、介入性研究、人类流行病学研究表明,Leptin可能是治疗阿尔茨海默氏症有前途的药物

J Neurosci:抑制大脑BACE1表达有望治疗阿尔茨海默氏症

目前为止,有关阿尔茨海默氏症的根本原因的大量研究证据指向了β-淀粉样蛋白的积累,β-淀粉样蛋白是一种对神经细胞有毒性的蛋白质。β-淀粉样蛋白的形成是由几种酶共同作用来完成的,其中就包括BACE1。大多数阿尔茨海默氏病患者BACE1的水平是升高的,这反过来又导致更多的脑损伤β-淀粉样蛋白的聚集。 相关研究论文发表在8月15日的Journal of Neuroscience杂志上,桑福德-伯纳姆医学

Baidu
map
Baidu
map
Baidu
map